HOPA appreciates the support of our Industry Relations Council.
Patient Assistance Program: Access360 (patient assistance/insurance investigation)
Patient Assistance Program: AZ & me (prescription savings)
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Patient Assistance Program: BMS Access Support
Bristol-Myers Squibb is a global biopharmaceutical company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail against serious diseases. Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, psychiatric disorders and rheumatoid arthritis.
Patient Assistance Program: Celgene Patient Support
Celgene Corporation (Nasdaq:CELG) is a global biopharmaceutical company that is helping healthcare providers turn incurable cancers into chronic, manageable diseases, as well as manage serious inflammatory conditions through innovative therapies. This dedication to medical progress goes hand-in-hand with our industry-leading patient support and access programs. Together, these aspects form the core of our commitment to patients worldwide.
Patient Assistance Program: Ease.US
Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in our efforts to bring them to patients globally. With growing revenues from the three resulting commercialized products – CABOMETYX®, COMETRIQ®, and COTELLIC® – we are reinvesting in our business to maximize the potential of our pipeline, which we intend to supplement with targeted business development activities and internal drug discovery, all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. For more information about Exelixis, please visit www.exelixis.com or follow @ExelixisInc on Twitter.
Patient Assistance Program: Genentech Access Solutions
At Genentech, we’re fundamentally transforming the way cancer is treated, with the goal of moving cancer toward a more manageable disease. Our commitment to this goal has enabled us to make significant contributions to the understanding of cancer and to translate this understanding into targeted, biologic-based therapies.
Patient Assistance Program: IncyteCARES.com
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.
Patient Assistance Program: Patient One Program
For more than five decades, Lilly Oncology has been dedicated to delivering innovative solutions that improve the care of people living with cancer. Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches that accelerate the pace and progress of cancer care. We also understand cancer care is complex, and we’re working to provide support services that are meaningful for you and your patients.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications across a variety of therapeutic areas, including oncology.
Patient Assistance Program: Pfizer RxPathways
Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline of biologics and small molecules, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to cure or control cancer with breakthrough medicines, to deliver the right drug for each patient at the right time.
Sandoz, with three decades developing and manufacturing biologics, is the global leader in biosimilars. Sandoz biosimilars are marketed in 60 countries with over 300 million patient days of experience. With the March 6, 2015 approval of a biosimilar in the US, we continue to demonstrate our determination to bring high quality affordable medicines to the community.
Patient Assistance Program: SeaGen Secure
Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. ADCETRIS™ (brentuximab vedotin) was approved by the FDA in August 2011. Seattle Genetics has three other clinical-stage programs: SGN-75, ASG-5ME and ASG-22 ME, and collaborations with leading biotechnology and pharmaceutical companies.
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapies.
Patient Assistance Program: CephalonCares® Foundation supports branded Teva Oncology products
Teva Oncology is a top 10 US oncology company that strives to improve the lives of people affected by cancer. Our focus is to provide solutions in hematologic malignancies, solid tumors and supportive care. Teva Oncology's vision is to change the course of cancer care one patient at a time.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com.
Follow us on www.twitter.com/amgen .
Patient Assistance Program: Coherus CompleteTM
Coherus BioSciences is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that can expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA® (pegfilgrastim-cbqv). Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs.
For additional information, please visit www.coherus.com
Patient Assistance Program: Helsinn Cares
Helsinn is a privately owned pharmaceutical group headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland, the U.S. and a representative office in China. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplements. Helsinn is an important player in cancer supportive care.
Patient Assistance Program: www.heronconnect.com
At Heron Therapeutics, our mission is to improve the lives of patients by developing innovative treatments that address important unmet patient needs. Our portfolio includes SUSTOL® (granisetron) extended-release injection, CINVANTI® (aprepitant) injectable emulsion, and a drug candidate under evaluation for non-opioid postoperative pain relief.
Jazz Pharmaceuticals is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, and commercializing differentiated products that address unmet medical needs. The company has a diverse portolio of products and product candidates in the areas of sleep, hematology/oncology, pain and psychiatry.
Patient Assistance Program: Merck Helps
Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.
In oncology, our goal is to translate breakthrough science into biomedical innovations to help people with cancer worldwide. For Merck Oncology, helping people fight cancer is our passion, supporting accessibility to our cancer medicines is our commitment, and pursuing research in immuno-oncology is our focus to potentially bring new hope to people with cancer. For more information about our oncology clinical trials, visit www.merck.com/clinicaltrials.
Patient Assistance Program: You&i Support Program
Pharmacyclics, an AbbVie company, is located in Sunnyvale, California, and is focused on developing and commercializing innovative small-molecule therapies for the treatment of certain cancers and immune-mediated diseases. Our hope is that we can change or improve the standard of care for the disease areas we treat or study to continually advance cancer care for patients.
For more information about our oncology clinical trials, visit http://www.btktrials.com/.
Patient Assistance Program: LIBTAYO Surround
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses a unique genetically-humanized mouse to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has built a world class clinical development organization that is working urgently to develop innovative cancer treatments. Taiho has an oral oncology pipeline consisting of both novel antimetabolic and selectively targeted agents. Advanced technology, dedicated researchers, and state of the art facilities are helping us to define the way the world treats cancer. It’s our work; it’s our passion; it’s our legacy.
Array BioPharma, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small molecule drugs to treat patients aﬄicted with cancer.
Eisai Inc. is the U.S. pharmaceutical operation of Eisai Co. Ltd., a research-based human healthcare (hhc) company that discovers, develops and markets products throughout the world. Eisai's areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care.
Novartis Oncology has emerged as a global leader in oncology through targeted research and open partnership in the pursuit of new therapies capable of transforming outcomes for people with cancer. Our research is driven by a distinctive scientific and clinical strategy focusing on unmet medical needs and disease pathways.
Patient Assistance Program: Walgreens allianceRx
Walgreens is dedicated to serving the needs of patients living with complex, chronic, and rare health and medical conditions, including cancer. Our pharmacists and pharmacy technicians, who have advanced cancer training and expertise, go beyond filling prescriptions. Whether it’s taking the lead on prior authorizations, helping ease copay costs, making limited-distribution drugs accessible, or providing adherence services, our team understands cancer patient needs and works with providers to support the prescribed regimen.